Ferroptosis: insight into the treatment of hepatocellular carcinoma.

IF 5.3 2区医学 Q1 ONCOLOGY Cancer Cell International Pub Date : 2024-11-13 DOI:10.1186/s12935-024-03559-z

Chuanjie Liao, Youwu He, Xinning Luo, Ganlu Deng

引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignances in the world, with high morbidity and mortality. Due to the hidden onset of symptoms, there are huge obstacles in early diagnosis, recurrence, metastasis and drug resistance. Although great strides have been made in the treatment of HCC, effective treatment options are still limited and achieving longer survival for patients remains urgent. Ferroptosis is a novel type of programmed cell death that is mainly caused by iron-dependent oxidative damage. With further investigations, ferroptosis has been proved to be associated with the occurrence and development of various tumors. This article reviews the regulatory mechanism and signal transduction pathways of ferroptosis, investigates the complex relationship between autophagy, sorafenib resistance and immunotherapy with ferroptosis involved in HCC, providing new ideas and directions for the treatment of HCC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

铁蛋白沉积症：治疗肝细胞癌的启示。

肝细胞癌（HCC）是世界上最常见的恶性肿瘤之一，发病率和死亡率都很高。由于发病隐匿，在早期诊断、复发、转移和耐药性方面存在巨大障碍。尽管在治疗 HCC 方面已经取得了长足进步，但有效的治疗方案仍然有限，延长患者的生存期仍然迫在眉睫。铁变态反应是一种新型的程序性细胞死亡，主要由铁依赖性氧化损伤引起。随着研究的深入，铁凋亡已被证实与多种肿瘤的发生和发展有关。本文综述了铁突变的调控机制和信号转导途径，探讨了自噬、索拉非尼耐药和免疫治疗与 HCC 中铁突变之间的复杂关系，为 HCC 的治疗提供了新的思路和方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.